Literature DB >> 9622100

Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.

B Couderc1, L Zitvogel, V Douin-Echinard, L Djennane, H Tahara, G Favre, M T Lotze, P D Robbins.   

Abstract

CD70 (CD27 ligand (CD27L)), CD153 (CD30L), and CD154 (CD40L) are members of the tumor necrosis factor family of costimulatory molecules and expressed on the surface of T cells that are important for both T- and B-cell help. We examined the capacity for expression of these tumor necrosis factor family members on tumor cells to induce an antitumor response either in the presence or absence of interleukin 12. Retroviral vectors were constructed that expressed high levels of membrane bound CD70, CD153, or CD154 following infection and selection of the murine tumor lines MCA 207 or TS/A. The genetically modified tumor cells expressing these molecules were able to stimulate splenic cell proliferation, demonstrating that the expressed costimulatory molecules were biologically active. When tested for tumor establishment, the expression of either CD70 or CD154 was able to slow tumor growth. Similarly, CD70 or CD154 were able to induce antitumor immunity at a higher frequency when tested in vaccination and therapy models. CD70 was able to induce antitumor immunity at a level similar to CD80 when tested either in the presence or absence of interleukin 12. Moreover, coexpression of CD70 and CD80 was able to synergize the induction of a higher frequency of antitumor immunity in a vaccination model. Taken together, our results suggest that CD154 and in particular CD70 are able to contribute to the induction of the immune response to tumor in murine models and thus may be of use for human clinical trials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622100

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  14 in total

1.  Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy.

Authors:  Jianping Huang; Keith W Kerstann; Mojgan Ahmadzadeh; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

Review 2.  Costimulatory and coinhibitory receptors in anti-tumor immunity.

Authors:  Gregory Driessens; Justin Kline; Thomas F Gajewski
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

3.  TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.

Authors:  Z-Z Yang; D M Grote; B Xiu; S C Ziesmer; T L Price-Troska; L S Hodge; D M Yates; A J Novak; S M Ansell
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

Review 4.  Internal ribosome entry site-based vectors for combined gene therapy.

Authors:  Edith Renaud-Gabardos; Fransky Hantelys; Florent Morfoisse; Xavier Chaufour; Barbara Garmy-Susini; Anne-Catherine Prats
Journal:  World J Exp Med       Date:  2015-02-20

5.  Opposing effects of CD70 costimulation during acute and chronic lymphocytic choriomeningitis virus infection of mice.

Authors:  Pablo Penaloza-MacMaster; Ata Ur Rasheed; Smita S Iyer; Hideo Yagita; Bruce R Blazar; Rafi Ahmed
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

6.  Collision tumor of primary laryngeal mucosal melanoma and invasive squamous cell carcinoma with IL-17A and CD70 gene over-expression.

Authors:  Sasis Sirikanjanapong; Biana Lanson; Milan Amin; Frank Martiniuk; Hideko Kamino; Beverly Y Wang
Journal:  Head Neck Pathol       Date:  2010-08-10

7.  CD70 Inversely Regulates Regulatory T Cells and Invariant NKT Cells and Modulates Type 1 Diabetes in NOD Mice.

Authors:  Cheng Ye; Benjamin E Low; Michael V Wiles; Todd M Brusko; David V Serreze; John P Driver
Journal:  J Immunol       Date:  2020-08-31       Impact factor: 5.422

8.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

Authors:  Xiao-Song Zhong; Maiko Matsushita; Jason Plotkin; Isabelle Riviere; Michel Sadelain
Journal:  Mol Ther       Date:  2009-09-22       Impact factor: 11.454

9.  The nature of activatory and tolerogenic dendritic cell-derived signal II.

Authors:  Ghaith Bakdash; Simone P Sittig; Tjeerd van Dijk; Carl G Figdor; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2013-02-28       Impact factor: 7.561

10.  Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation.

Authors:  Ramon Arens; Koen Schepers; Martijn A Nolte; Michiel F van Oosterwijk; René A W van Lier; Ton N M Schumacher; Marinus H J van Oers
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.